CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD

European Respiratory Journal

Volumn 35, Issue 1, 2010, Pages 132-137

  Machado, M C L ^a   Vollmer, W M ^d   Togeiro, S M ^a   Bilderback, A L ^e   Oliveira, M V C ^c   Leitao F S ^a,c   Queiroga Jr , F ^a   Lorenzi Filho, G ^b   Krishnane, J A ^f  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c São Paulo State Hospital   (Brazil)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

Chronic obstructive pulmonary disease; Continuous positive airway pressure; Long term oxygen therapy; Obstructive sleep apnoea syndrome; Survival

Indexed keywords

ADULT; AGED; ARTICLE; BRAZIL; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HAZARD RATIO; HUMAN; HYPOXEMIA; LONG TERM CARE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTPATIENT; OXYGEN THERAPY; PATIENT COMPLIANCE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SLEEP APNEA SYNDROME; SURVIVAL RATE;

AGED; ANOXIA; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYGEN INHALATION THERAPY; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SLEEP APNEA SYNDROMES; SURVIVAL RATE;

EID: 75149158614     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00192008     Document Type: Article

References (37)

1. Murray CJL, Lopes AD. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121: Suppl., 121S-126S.
2. Petty TL. Definition, epidemiology, course, and prognosis of COPD. Clin Cornerstone 2003; 5: 1-10.
3. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-212.
4. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
5. Banno K, Kryger M. Sleep apnea: clinical investigations in humans. Sleep Med 2007; 8: 400-426.
6. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease. Cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25.
7. Wolk R, Kara T, Somers VK. Sleep-disordered breathing and cardiovascular disease. Circulation 2003; 108: 9-12.
8. Weitzenblum E, Chaouat A. Sleep and chronic obstructive pulmonary disease. Sleep Med Rev 2004; 8: 281-294.
9. Chaouat A, Weitzenblum E, Krieger J, et al. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am Rev Respir Dis 1995; 151: 82-86.
10. Bhullar S, Phillips B. Sleep in COPD patients. COPD 2005; 2: 355-361.
11. Lavie P, Herer P, Peled R, et al. Mortality in sleep apnoea: a multivariate analysis of risk factors. Sleep 1995; 18: 149-157.
12. Lavie P, Herer P, Lavie L. Mortality risk factors in sleep apnoea: a matched case-control study. J Sleep Res 2007; 16: 128-134.
13. De Miguel J, Cabello J, Sanches-Alarcos JMF, et al. Long-term effects of treatment with nasal continuous positive airway pressure on lung function in patients with overlap syndrome. Sleep Breath 2002; 6: 3-10.
14. Mansfield D, Naughton MT. Effects of continuous positive airway pressure on lung function in patients with chronic obstructive pulmonary disease and sleep disordered breathing. Respirology 1999; 4: 365-370.
15. Veale D, Chailleux E, Hoorelbeke-Ramon A, et al. Mortality of sleep apnoea patients treated by nasal continuous positive airway pressure registered in the ANTADIR observatory. Eur Respir J 2000; 15: 326-331.
16. Marti S, Sampol G, Muñoz X, et al. Mortality in severe sleep apnoea/hypopnoea syndrome patients: impact of treatment. Eur Respir J 2002; 20: 1511-1518.
17. Campos-Rodriguez F, Peña-Griñan N, Reyes-Nuñez N, et al. Mortality in obstructive sleep apnea-hypopnea patients treated with positive airway pressure. Chest 2005; 128: 624-633.
18. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observation study. Lancet 2005; 365: 1046-1053.
19. Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353: 2034-2041.
20. Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005; 353: 2025-2033.
21. Celli BR, Snider GL, Heffner J, et al. American Thoracic Society statement: standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: 77S-120S.
22. Pauwels RA, Buist AS, Calverly PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
23. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22: 667-689.
24. Gay P, Weaver T, Loube D, et al. Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. Sleep 2006; 29: 381-401.
25. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-383.
26. Fundação Sistema Estadual de Análise de Dados [(São Paulo) State System of Data Analysis Foundation]. Índice Paulista de Vulnerabilidade Social [Paulista Index of Social Vulnerability]. www.seade.gov.br/produtos/ipvs/apresentacao.php Date last updated: 2000. Date last accessed: May 2009.
27. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-1218.
28. Indications for Polysomnography Task Force, American Sleep Disorders Association Standards of Practice CommitteePractice parameters for the indications for polysomnography and related procedures. Sleep 1997; 20: 406-422.
29. Sanders MH, Black J, Constantino JP, et al. Diagnosis of sleepdisordered breathing by half-night polysomnography. Am Rev Respir Dis 1991; 144: 1256-1261.
30. Rechtschaffen A, Kales A, eds. A Manual of Standardized Terminology, Techniques and Scoring for Sleep Stages of Human Subjects. Washington DC, Government Printing Office, 1968.
31. Bonnet M, Carley D, Carskadon M, et al. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992; 15: 173-184.
32. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49-53.
33. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. A clinical trial. Ann Intern Med 1980; 93: 391-398.
34. Report of long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysemaReport of the Medical Research Council Working Party. Lancet 1981; 1: 681-685.
35. Marti S, Munõz X, Rios J, et al. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J 2006; 27: 689-696.
36. Drager LF, Bortolotto LA, Lorenzi MC, et al. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 613-618.
37. Eurich DT, Marrie TJ, Johnstone J, et al. Mortality reduction with influenza vaccine in patients with pneumonia outside "flu"season. Pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008; 178: 527-533.